An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Published . Updated .
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
Directly affected
- ALKS Alkermes
Named in this report.
- ABBV AbbVie
Named in this report.
- LLY Eli Lilly
Named in this report.
Indirectly affected
- SUPX SUPERX AI TECHNOLOGY LTD
GA selected SUPX as a RELATED security because its canonical security name directly matches this event's themes: technology, ai. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ABAT AMERICAN BATTERY TECHNOLOGY
GA selected ABAT as a RELATED security because its canonical security name directly matches this event's themes: technology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACM AECOM TECHNOLOGY CORP
GA selected ACM as a RELATED security because its canonical security name directly matches this event's themes: technology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- AOSL ALPHA & OMEGA SEMICONDUCTOR LT SHS
GA selected AOSL as a RELATED security because its canonical security name directly matches this event's themes: semiconductor. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
Source: BioPharma Dive
How far Eli Lilly (LLY) has moved since 22 Sep 2026
Since the first closing price after “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide,” Eli Lilly (LLY) is +7.75%. The S&P 500 fund (SPY) is -0.17% over the same days, a +7.92% difference versus the market.
Filings that name Eli Lilly (LLY) around 22 Sep 2026
- Rohit Khanna buy Eli Lilly (LLY) ($1,001 - $15,000). That is 18 days before publication, inside 30 days. The filing is listed beside the story “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide.”
- Donald J Trump buy Aecom (ACM) ($1,001 - $15,000). That is 25 days before publication, inside 30 days. The filing is listed beside the story “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide.”
- Donald J Trump sell Aecom (ACM) ($1,001 - $15,000). That is 29 days before publication, inside 30 days. The filing is listed beside the story “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Eli Lilly (LLY)
Companies carried with this story
- LLY Eli Lilly
In “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide,” Eli Lilly (LLY) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names ELI LILLY & CO in the summary; GA resolved that company to LLY
- SUPX SuperX AI Technology
In “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide,” SuperX AI Technology (SUPX) is linked, with no stored direction, medium confidence. Reason on file: GA selected SUPX as a RELATED security because its canonical security name directly matches this event's themes: technology, ai. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ABAT American Battery Technology
American Battery Technology (ABAT) is linked, with no stored direction, medium confidence in the 22 Sep 2026 story “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide.” Reason on file: GA selected ABAT as a RELATED security because its canonical security name directly matches this event's themes: technology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 22 Sep 2026 story “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACM Aecom
Aecom (ACM) is linked, with no stored direction, medium confidence in the 22 Sep 2026 story “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide.” Reason on file: GA selected ACM as a RELATED security because its canonical security name directly matches this event's themes: technology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- AOSL Alpha & Omega Semiconductor
For “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide,” Alpha & Omega Semiconductor (AOSL) is linked, with no stored direction, medium confidence. Reason on file: GA selected AOSL as a RELATED security because its canonical security name directly matches this event's themes: semiconductor. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 22 Sep 2026 story “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Eli Lilly (LLY)
On 22 Sep 2026, “An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide” is the story that connects Eli Lilly (LLY) to this story.
What ties Eli Lilly (LLY) to the headline is this: The reported development directly names ELI LILLY & CO in the summary; GA resolved that company to LLY
SuperX AI Technology (SUPX) is here too. Its reason reads: GA selected SUPX as a RELATED security because its canonical security name directly matches this event's themes: technology, ai. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for Eli Lilly (LLY), and the dates in the story
ABAT traded between 1.42 and 2.42 across 20 sessions. The latest close on file is 1.44. LLY traded between 1131.55 and 1275.56 across 20 sessions. The latest close on file is 1240.65. SUPX traded between 6.15 and 7.09 across 10 sessions. The latest close on file is 6.72.
A simple score for Eli Lilly (LLY)
46 out of 100
“An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.